Therapeutic compositions containing macitentan
AssigneeActelion Pharmaceuticals Ltd.
InventorMartine Clozel
Life of this patent
Estimating the term…
Abstract
The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.
Claims19
A method for the treatment of a disease selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction, angina pectoris and pulmonary fibrosis, comprising administering an effective amount of the compound of formula (I)
- in free or pharmaceutically acceptable salt form, in combination with an effective amount of at least one compound having prostacyclin receptor (IP) agonist properties selected from 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide and {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid, in free or pharmaceutically acceptable salt form.
A method for the treatment of pulmonary arterial hypertension comprising administering an effective amount of the compound of formula (I)
- in free or pharmaceutically acceptable salt form, in combination with an effective amount of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide, in free or pharmaceutically acceptable salt form.
Dependencies are inferred from the claim text.